CAM
BMRN icon

Connacht Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Connacht Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,069
Closed -$359K – 125
2021
Q4 		$359K Buy
+4,069
New +$336K 0.35% 83

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Connacht Asset Management's BMRN Position: Q1 2022 in Review

Connacht Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 4,069 shares — an estimated $359K sold.

Connacht Asset Management first reported a position in BMRN in Q4 2021 and held it in 1 quarter. The position peaked at $359K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Connacht Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Connacht Asset Management sold 4,069 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $359K.
  • Connacht Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Connacht Asset Management's BioMarin Pharmaceuticals position peaked at $359K in Q4 2021.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Connacht Asset Management's 13F filing for Q1 2022, filed 16 May 2022.